Modeling Meropenem Treatment, Alone and in Combination with Daptomycin, for KPC-Producing Klebsiella pneumoniae Strains with Unusually Low Carbapenem MICs

被引：10

作者：

Gagetti, P. ^{[1
,2
]}

Pasteran, F. ^{[2
]}

Martinez, M. P. ^{[1
]}

Fatouraei, M. ^{[1
]}

Gu, J. ^{[1
]}

Fernandez, R. ^{[1
]}

Paz, L. ^{[1
]}

Rose, W. E. ^{[3
]}

Corso, A. ^{[2
]}

Rosato, A. E. ^{[1
]}

机构：

[1] Houston Methodist Res Inst, Houston, TX USA

[2] INEI ANLIS Dr Carlos Malbran, Serv Antimicrobianos, Buenos Aires, DF, Argentina

[3] Univ Wisconsin, Sch Pharm, Madison, WI USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2016年 / 60卷 / 08期

基金：

美国国家卫生研究院;

关键词：

STAPHYLOCOCCUS-AUREUS; IN-VITRO; THERAPY; PHARMACODYNAMICS; HETERORESISTANCE; SIMULATION; MORTALITY;

D O I：

10.1128/AAC.00168-16

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Klebsiella pneumoniae strains producing K. pneumoniae carbapenemase (KPC) cause serious infections in debilitated and immunocompromised patients and are associated with prolonged hospital stays and increased mortality rates. Daptomycin is a lipopeptide used against Staphylococcus aureus infection and considered inactive against Gram-negative bacteria. We investigated the effectiveness of a daptomycin-meropenem combination by synergy kill curve and a pharmacokinetic/pharmacodynamic model. The combination may represent a novel therapeutic strategy against infections caused by KPC-producing K. pneumoniae strains.

引用

页码：5047 / 5050

页数：4

共 16 条

[1] INVITRO MODEL FOR SIMULTANEOUS SIMULATION OF THE SERUM KINETICS OF 2 DRUGS WITH DIFFERENT HALF-LIVES
BLASER, J
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1985, 15 : 125 - 130
[2] Pharmacodynamics of Minocycline against Staphylococcus aureus in an In Vitro Pharmacokinetic Model
Bowker, Karen E.
Noel, Alan R.
MacGowan, Alasdair P.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (12) : 4370 - 4373
[3] Comparative pharmacodynamics of meropenem using an in-vitro model to simulate once, twice and three times daily dosing in humans
Bowker, KE
Holt, HA
Lewis, RJ
Reeves, DS
MacGowan, AP
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (04) : 461 - 467
[4] What Is the Appropriate Meropenem MIC for Screening of Carbapenemase-Producing Enterobacteriaceae in Low-Prevalence Settings?
Fattouh, Ramzi
Tijet, Nathalie
McGeer, Allison
Poutanen, Susan M.
Melano, Roberto G.
Patel, Samir N.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (03) : 1556 - 1559
[5] β-Lactams Increase the Antibacterial Activity of Daptomycin against Clinical Methicillin-Resistant Staphylococcus aureus Strains and Prevent Selection of Daptomycin-Resistant Derivatives
Mehta, Shrenik
Singh, Christopher
Plata, Konrad B.
Chanda, Palas K.
Paul, Arundhati
Riosa, Sarah
Rosato, Roberto R.
Rosato, Adriana E.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (12) : 6192 - 6200
[6] Imipenem heteroresistance: high prevalence among Enterobacteriaceae Klebsiella pneumoniae carbapenemase producers
Nodari, Carolina Silva
Ribeiro, Vanessa Bley
Barth, Afonso Luis
[J]. JOURNAL OF MEDICAL MICROBIOLOGY, 2015, 64 : 124 - 126
[7] Carbapenem resistance in Enterobacteriaceae: here is the storm!
Nordmann, Patrice
Dortet, Laurent
Poirel, Laurent
[J]. TRENDS IN MOLECULAR MEDICINE, 2012, 18 (05) : 263 - 272
[8] Petrosillo N, 2013, EXPERT REV ANTI-INFE, V11, P159, DOI [10.1586/eri.12.162, 10.1586/ERI.12.162]
[9] Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance
Pitout, Johann D. D.
Nordmann, Patrice
Poirel, Laurent
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (10) : 5873 - 5884
[10] Characteristics of Meropenem Heteroresistance in Klebsiella pneumoniae Carbapenemase (KPC)-Producing Clinical Isolates of K-pneumoniae
Pournaras, Spyros
Kristo, Ioulia
Vrioni, Georgia
Ikonomidis, Alexandros
Poulou, Aggeliki
Petropoulou, Dimitra
Tsakris, Athanassios
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2010, 48 (07) : 2601 - 2604

← 1 2 →